These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20029947)

  • 21. Myelofibrosis--pathophysiology and treatment.
    Cole DR; Pung J; Pung F; Cole DF
    Int J Clin Pharmacol Biopharm; 1979 Feb; 17(2):68-70. PubMed ID: 370037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unusual evolution and chromosome aberrations in a patient with myelofibrosis with myeloid metaplasia.
    Zaccaria A; Finelli C; Testoni N; Visani G; Ricci P; Rosti G; Pileri S; Biagini G; Tura S
    Haematologica; 1985; 70(3):236-9. PubMed ID: 3932152
    [No Abstract]   [Full Text] [Related]  

  • 23. A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis.
    George B; Kerridge I; Gottlieb D; Huang G; Hertzberg M; Svennilson J; Bradstock K
    Bone Marrow Transplant; 2008 Oct; 42(8):567-8. PubMed ID: 18660841
    [No Abstract]   [Full Text] [Related]  

  • 24. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
    Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
    Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unrelated stem cell transplant for infantile idiopathic myelofibrosis.
    Domm J; Calder C; Manes B; Crossno C; Correa H; Frangoul H
    Pediatr Blood Cancer; 2009 Jul; 52(7):893-5. PubMed ID: 19241452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis.
    Kiss TL; Messner HA; Galal A; Lipton J
    Bone Marrow Transplant; 2005 Jan; 35(2):213-4. PubMed ID: 15531899
    [No Abstract]   [Full Text] [Related]  

  • 28. [Acute myelofibrosis].
    Woessner S
    Med Clin (Barc); 1990 Jun; 95(1):15-7. PubMed ID: 2232945
    [No Abstract]   [Full Text] [Related]  

  • 29. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
    [No Abstract]   [Full Text] [Related]  

  • 31. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
    Tefferi A
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The etiology, clinical features, and new therapy for primary myelofibrosis].
    Shimoda K
    Rinsho Ketsueki; 2006 Feb; 47(2):89-95. PubMed ID: 16529010
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
    Tefferi A; Dingli D; Li CY; Dewald GW
    Cancer; 2005 Oct; 104(8):1656-60. PubMed ID: 16104040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
    Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
    Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of abnormal clones in single colonies from a patient with idiopathic myelofibrosis.
    Suda T; Sato Y; Suda J; Kubota K; Saito M; Miura Y
    Prog Clin Biol Res; 1986; 215():355-9. PubMed ID: 3725786
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term remission of myelofibrosis following nonmyeloablative allogeneic peripheral blood progenitor cell transplantation in older age: the Scripps Clinic experience.
    Greyz N; Miller WE; Andrey J; Mason J
    Bone Marrow Transplant; 2004 Aug; 34(3):273-4. PubMed ID: 15170157
    [No Abstract]   [Full Text] [Related]  

  • 39. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
    Cervantes F; Barosi G
    Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trisomy 13 in a patient with idiopathic myelofibrosis.
    Gozzetti A; Crupi R; Tozzuoli D; Fabbri A; Bocchia M; Lauria F
    Cancer Genet Cytogenet; 2005 Jan; 156(2):185. PubMed ID: 15642403
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.